AR076507A1 - Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 - Google Patents
Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6Info
- Publication number
- AR076507A1 AR076507A1 ARP100101465A ARP100101465A AR076507A1 AR 076507 A1 AR076507 A1 AR 076507A1 AR P100101465 A ARP100101465 A AR P100101465A AR P100101465 A ARP100101465 A AR P100101465A AR 076507 A1 AR076507 A1 AR 076507A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- homopiperazine
- homopiperazinyl
- piperazine
- respond
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract 4
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 title abstract 2
- -1 HOMOPIPERAZINYL Chemical class 0.000 title abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 239000011737 fluorine Chemical group 0.000 abstract 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos de N-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina), con composiciones farmacéuticas que contienen a los mismos y su uso en terapias. Los compuestos son apropiados, en particular, para tratar enfermedades que responden a la modulacion del receptor de serotonina 5-HT6, en donde R es un enlace o un grupo N-R4, R1 es hidrogeno o metilo; R2 es hidrogeno o metilo; R3 es hidrogeno, alquilo C1-3, fluor, alcoxi C1-2 o alcoxi C1-2 fluorado; R4 es hidrogeno, alquilo C1-4, cicloalquilo C3-4 o cicloalquil C3-4-CH2-; R5 es hidrogeno, fluor, cloro, alquilo C1-2, alquilo C1-2 fluorado, alcoxi C1-2 o alcoxi C1-2 fluorado; R6 es hidrogeno, fluor o cloro; y n es 1 o 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17405409P | 2009-04-30 | 2009-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076507A1 true AR076507A1 (es) | 2011-06-15 |
Family
ID=42236832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101465A AR076507A1 (es) | 2009-04-30 | 2010-04-30 | Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8076326B2 (es) |
| EP (1) | EP2432769B1 (es) |
| JP (1) | JP5718898B2 (es) |
| KR (1) | KR20120016639A (es) |
| CN (1) | CN102459197B (es) |
| AR (1) | AR076507A1 (es) |
| AU (1) | AU2010243585B2 (es) |
| BR (1) | BRPI1011875A2 (es) |
| CA (1) | CA2759482A1 (es) |
| CL (1) | CL2011002653A1 (es) |
| CO (1) | CO6450637A2 (es) |
| CR (1) | CR20110604A (es) |
| DO (1) | DOP2011000326A (es) |
| EC (1) | ECSP11011468A (es) |
| ES (1) | ES2536779T3 (es) |
| IL (1) | IL215642A (es) |
| MX (1) | MX2011011520A (es) |
| NZ (1) | NZ595698A (es) |
| PE (1) | PE20120881A1 (es) |
| RU (1) | RU2535200C2 (es) |
| SG (1) | SG175187A1 (es) |
| TW (1) | TWI465438B (es) |
| UA (1) | UA107080C2 (es) |
| UY (1) | UY32604A (es) |
| WO (1) | WO2010125134A1 (es) |
| ZA (1) | ZA201107569B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| EP2280705B1 (en) | 2008-06-05 | 2014-10-08 | Glaxo Group Limited | Novel compounds |
| ES2445199T3 (es) | 2008-06-05 | 2014-02-28 | Glaxo Group Limited | Derivados de benzpirazol como inhibidores de PI3-quinasas |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| ES2876933T3 (es) | 2009-04-30 | 2021-11-15 | Glaxo Group Ltd | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas |
| US8343959B2 (en) * | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| WO2012059432A1 (en) * | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
| US20140120036A1 (en) * | 2012-01-06 | 2014-05-01 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| EP2928866A1 (en) * | 2012-12-10 | 2015-10-14 | F. Hoffmann-La Roche AG | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS |
| JP2016510781A (ja) * | 2013-03-15 | 2016-04-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＲＯＲｃモジュレーターとしてのアリールスルファミド及びスルファミン酸誘導体 |
| US9663498B2 (en) | 2013-12-20 | 2017-05-30 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| EP3134392B1 (en) * | 2014-04-19 | 2019-01-02 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
| EP4419105A4 (en) * | 2021-10-20 | 2025-12-24 | Yousef Najajreh | ALLOSTERIC INHIBITOR COMPOUNDS TO OVERCOME CANCER RESISTANCE |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| HUP0003073A3 (en) * | 1997-07-11 | 2002-10-28 | Smithkline Beecham Plc | Benzenesulfonamide derivatives, process for producing them and their use as medicines |
| GB9818914D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| SE0002739D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
| EP1406884A1 (en) | 2001-05-11 | 2004-04-14 | Biovitrum Ab | Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
| IL158590A0 (en) * | 2001-06-11 | 2004-05-12 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| NZ530742A (en) * | 2001-08-10 | 2007-07-27 | Hoffmann La Roche | Arylsulfonyl derivatives with 5-HT6 receptor affinity |
| CA2476350C (en) * | 2002-02-22 | 2011-04-05 | Pharmacia & Upjohn Company | Pyridyl sulfone derivatives as 5-ht receptor antagonists |
| GB0305575D0 (en) | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| AU2005266448A1 (en) | 2004-07-28 | 2006-02-02 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
| GB0419192D0 (en) * | 2004-08-27 | 2004-09-29 | Merck Sharp & Dohme | Therapeutic agents |
| WO2007108742A1 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel tetralins as 5-ht6 modulators |
| PE20080191A1 (es) * | 2006-04-19 | 2008-03-10 | Abbott Gmbh & Co Kg | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 |
| WO2008087123A2 (en) | 2007-01-16 | 2008-07-24 | Solvay Pharmaceuticals B.V. | Use of 5-ht6 antagonists to prevent relapse into addiction |
-
2010
- 2010-04-29 KR KR1020117028393A patent/KR20120016639A/ko not_active Ceased
- 2010-04-29 BR BRPI1011875A patent/BRPI1011875A2/pt not_active IP Right Cessation
- 2010-04-29 PE PE2011001879A patent/PE20120881A1/es not_active Application Discontinuation
- 2010-04-29 WO PCT/EP2010/055789 patent/WO2010125134A1/en not_active Ceased
- 2010-04-29 JP JP2012507761A patent/JP5718898B2/ja not_active Expired - Fee Related
- 2010-04-29 MX MX2011011520A patent/MX2011011520A/es active IP Right Grant
- 2010-04-29 UA UAA201114123A patent/UA107080C2/ru unknown
- 2010-04-29 SG SG2011074325A patent/SG175187A1/en unknown
- 2010-04-29 CA CA2759482A patent/CA2759482A1/en not_active Abandoned
- 2010-04-29 RU RU2011148583/04A patent/RU2535200C2/ru not_active IP Right Cessation
- 2010-04-29 CN CN201080030335.8A patent/CN102459197B/zh not_active Expired - Fee Related
- 2010-04-29 EP EP10719748.5A patent/EP2432769B1/en active Active
- 2010-04-29 NZ NZ595698A patent/NZ595698A/en not_active IP Right Cessation
- 2010-04-29 AU AU2010243585A patent/AU2010243585B2/en not_active Ceased
- 2010-04-29 ES ES10719748.5T patent/ES2536779T3/es active Active
- 2010-04-30 TW TW099113996A patent/TWI465438B/zh not_active IP Right Cessation
- 2010-04-30 US US12/770,837 patent/US8076326B2/en not_active Expired - Fee Related
- 2010-04-30 UY UY0001032604A patent/UY32604A/es not_active Application Discontinuation
- 2010-04-30 AR ARP100101465A patent/AR076507A1/es not_active Application Discontinuation
-
2011
- 2011-10-09 IL IL215642A patent/IL215642A/en not_active IP Right Cessation
- 2011-10-14 ZA ZA2011/07569A patent/ZA201107569B/en unknown
- 2011-10-25 CL CL2011002653A patent/CL2011002653A1/es unknown
- 2011-10-25 DO DO2011000326A patent/DOP2011000326A/es unknown
- 2011-11-03 CO CO11149288A patent/CO6450637A2/es active IP Right Grant
- 2011-11-15 CR CR20110604A patent/CR20110604A/es unknown
- 2011-11-21 EC EC2011011468A patent/ECSP11011468A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076507A1 (es) | Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 | |
| EA201992215A1 (ru) | Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr) | |
| EA201592252A1 (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
| PE20190913A1 (es) | Derivados aromaticos de sulfonamida | |
| UY35377A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
| CL2013000380A1 (es) | Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion. | |
| PE20130382A1 (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| CR20120110A (es) | Compuestos heterocíclicos y usos de los mismos | |
| CL2013003731A1 (es) | Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad. | |
| PA8845601A1 (es) | Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1) | |
| EA200870360A1 (ru) | Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| EA201401141A1 (ru) | Средства для лечения нарушений, вовлекающих модуляцию рецепторов рианодина | |
| EA201691447A1 (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
| CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
| EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| CL2012001072A1 (es) | Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas. | |
| MX391392B (es) | ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a. | |
| PE20170083A1 (es) | Nuevos compuestos | |
| CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
| CR20130056A (es) | Derivados heterocíclicos fusionados como moduladores s1p | |
| EA200801001A1 (ru) | Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине | |
| PE20180316A1 (es) | Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda | |
| ECSP13012453A (es) | 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3 | |
| AR072547A1 (es) | 6- (1-piperazinil)-piridazinas sustituidas como antagonistas del receptor 5-ht6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |